This study aimed to assess the safety, tolerability, efficacy, and compliance of a risperidone
long-acting injection (RLAI) formulation for the maintenance treatment of stabilized bipolar …

Objective. To investigate the maintained efficacy of antipsychotic therapy in stable patients
with bipolar disorder transitioned directly to risperidone long-acting injectable (RLAI) …

DISCUSSION Oral risperidone received approval from the US Food and Drug Administration
for use in bipolar disorder include monotherapy for the short-term treatment of acute manic …

Objective: No large controlled trials have evaluated adjunctive maintenance treatment with
long‐acting injectable antipsychotics in patients with bipolar disorder. This study assessed …

BACKGROUND: Treatment adherence is a significant problem in patients with bipolar
disorder. This study was designed to determine the efficacy of risperidone long-acting …

Background The objective of this exploratory analysis was to characterize efficacy and onset
of action of a 3-month treatment period with risperidone long-acting injection (RLAI) …

Importance of the field: It is very rare for patients with bipolar disorder to have a single
episode of mania or depression over a lifetime and the vast majority of these individuals …

Poor adherence to pharmacotherapy during maintenance-phase treatment of bipolar
disorder is a common occurrence, exposing patients to a high risk of illness relapses …

Bipolar disorder is a multidimensional illness typified by fluctuating periods of depression
and mania, cognitive dysfunction, abnormal circadian rhythms, and multiple comorbid …

In the last few years, oral second-generation antipsychotics have demonstrated mood-
stabilizing properties and are now widely used in the treatment of bipolar disorder …